Reports
Sale
Global Cardiotoxicity Market Size, Share, Trends, Report: By Type: Diagnostic, Treatment; By End User: Pharmaceutical and Biotechnology Company, Academic and Research Institutes, Contact Research Organizations, Others; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032
Cardiotoxicity Market Size
The global cardiotoxicity market is expected to grow at a CAGR of 8.39% during the forecast period of 2024-2032, driven by the growing prevalence of cancer as well as emphasis on its early detection across the globe.
Cardiotoxicity Market Outlook
- The increasing incidence of cancer is a key cause of cardiotoxicity as it is often associated with a reaction against certain cancer treatments or drugs.
- One of the major market trends is the rising collaborations between pharmaceutical and diagnostic companies.
- North America is expected to lead the market share in the forecast period. This can be attributed to its strong healthcare system and large investments in research.
Cardiotoxicity Market Overview
Cardiotoxicity is a medical phenomenon where the utilization of some chemical agents results in toxic action on cardiac tissue. Cardiotoxicity risk ranges from minimal to severe, depending on the medication used, the dose given, and the period of use. Some of the signs are coughing with or without sputum, dyspnea, chest pain, palpitations, fatigue, and lower extremity edema. In the worst cases, it results in heart failure, as indicated by aspects such as increased weight, breathing problems, and protracted coughing episodes. The diagnosis of this disease begins with a history and physical examination of the patient, followed by an electrocardiogram, echocardiogram, cardiac MRI, blood tests, and even a biopsy, which may occasionally be done.
Cardiotoxicity Market Growth Drivers
Growing Use of Cardiotoxic Drugs to Boost the Market Demand
A rising prevalence of drugs that can harm the heart in cancer treatments is a main force that is propelling the market for cardiotoxicity. Chemotherapeutic agents, targeted therapies, and radiation therapy can cause cardiotoxicity. Moreover, the latest advances in the field of oncology have contributed to the broadened utilization of new chemotherapeutic agents, many of which have cardiotoxicity.
According to the American Cancer Society, the number of new cancer cases in the United States reached 1,958,310, while 609,820 people died from cancer in 2023. This further emphasizes the necessity for heart protection measures, early detection techniques, and all-inclusive management procedures. The growing geriatric population base, which is naturally more susceptible to both cancer as well as other cardiac issues is also boosting the demand for cardiotoxicity monitoring and treatment.
Cardiotoxicity Market Trends
| Key Trends | Impact |
| Technological Advancements in diagnostics | The market's growth is driven by the ongoing developments in diagnostic techniques, such as cardiac biomarkers, imaging technologies, and wearable devices. This can lead to earlier identification and personalized patient recovery of cardiotoxicity, thus improving patient outcomes. |
| Development of Novel Therapeutic Interventions | Scientists and drug companies are focused on finding new medicines or bringing some modification in the existing ones to tackle the causes of heart problems caused by drugs. |
| Expansion of Healthcare Infrastructure in Emerging Markets | The growth of healthcare facilities in developing countries is a significant market trend likely to lead to market expansion. Better access to medical services and new medical technologies can help find and treat cardiotoxicity early in these areas. |
| Collaboration Between Pharmaceutical and Diagnostic Companies | Drug companies and diagnostic firms are working together to create tests that can identify the risk of cardiotoxicity and help doctors choose the best treatment for each patient. Such partnerships can improve the safety and effectiveness of patient care significantly. |
Recent Developments in the Cardiotoxicity Market
The market is witnessing increased research and development initiatives aimed at recognising the main cause of cardiotoxicity. For instance, in April 2024, the scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) reported that anthracyclines, one of the most common chemotherapy treatments, damage patients' hearts. Anthracycline-induced cardiotoxicity affects about one-third of cancer survivors. More than 3 million patients in the European continent are treated with this drug class annually. Around 5% of the patients can get a life-threatening cardiac injury, which may result in chronic heart failure, and disrupt a patient’s quality of life.
Cardiotoxicity Market Segmentation
Market Breakup by Type
- Diagnostic
- Analyzers and Instruments
- Reagents and Kits
- Software and Services
- Others
- Treatment
- Tyrosine Kinase Inhibitors
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
- Others
Market Breakup by End User
- Pharmaceutical and Biotechnology Company
- Academic and Research Institutes
- Contact Research Organizations
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Cardiotoxicity Market Share
Market Segmentation by End User Expected to Boost the Market Growth
The market segmentation based on end users, includes pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and others. Out of these, pharmaceutical and biotechnology companies are expected to hold a significant market share. It can be attributed to their massive research and development activities, increased investment in advanced technologies, and strong sources for the assessment of cardiac safety.
Cardiotoxicity Market Analysis by Region
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these regions, North America is likely to hold the largest share of the market because of the well-developed infrastructure of the healthcare industry, substantial research expenditure, and a higher incidence of cancer. Europe, with a robust regulatory landscape is expected to hold a notable market share. In the Asia Pacific region, the market potential for Japan and India is on the rise because of the rising healthcare costs, a growing pharmaceutical market, and escalating awareness of the many cardiac health problems.
Leading Players in the Cardiotoxicity Market
The key features of the market report include patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Admescope Ltd
Founded in 2011 and headquartered in Oulu, Finland, this company offers services important and related to the assessment of cardiotoxicity. Their portfolio consists of in vitro assays that include drug metabolism and pharmacokinetics (DMPK), which play an important role in making assessments of the cardiac safety profiles of chemical entities of drugs.
Axol Bioscience Ltd.
Founded in 2013 and headquartered in Cambridge, UK, the company offers commercial products such as cardiotoxicity assay kits that contain reagents and protocols for functional assays as well as toxicity screening in cardiomyocyte models.
Other companies include Evotec BioSystems GmbH, Stemina Biomarker Discovery Inc., Eurofins Panlabs Discovery Services, Molecular Devices LLC., Curia Global Holdings Ltd, Aragen Life Sciences Limited, Anbio Biotechnology Limited, WuXi AppTec Co., Ltd., Creative Bioarray, Emka Technologies Private Limited, Enzo Life Sciences, Inc., Novartis AG, Pfizer & Co., Inc., and Amgen Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Cardiotoxicity Market
- What was the cardiotoxicity market value in 2023?
- What is the cardiotoxicity market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What are the major factors aiding the cardiotoxicity market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major cardiotoxicity market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the cardiotoxicity market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What is the market segmentation based on type?
- What is the market segmentation based on end user?
- Why do pharmaceutical companies prioritize cardiotoxicity testing?
- How does the regulatory landscape in Europe impact cardiotoxicity testing practices?
- What factors are driving growth in the cardiotoxicity market in the Asia Pacific?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cardiotoxicity Market Overview
3.1 Global Cardiotoxicity Market Historical Value (2017-2023)
3.2 Global Cardiotoxicity Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Cardiotoxicity Market Landscape*
5.1 Global Cardiotoxicity Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Cardiotoxicity: Product Landscape
5.2.1 Analysis by Type
6 Global Cardiotoxicity Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Cardiotoxicity Market Segmentation (2017-2032)
7.1 Global Cardiotoxicity Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Diagnostic
7.1.2.1 Analyzers and Instruments
7.1.2.2 Reagents and Kits
7.1.2.3 Software and Services
7.1.2.4 Others
7.1.3 Treatment
7.1.3.1 Tyrosine Kinase Inhibitors
7.1.3.2 Antibiotics
7.1.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
7.1.3.4 Others
7.2 Global Cardiotoxicity Market (2017-2032) by End User
7.2.1 Market Overview
7.2.2 Pharmaceutical and Biotechnology Company
7.2.3 Academic and Research Institutes
7.2.4 Contact Research Organizations
7.2.5 Others
7.3 Global Cardiotoxicity Market (2017-2032) by Region
7.3.1 Market Overview
7.3.2 North America
7.3.3 Europe
7.3.4 Asia Pacific
7.3.5 Latin America
7.3.6 Middle East and Africa
8 North America Cardiotoxicity Market (2017-2032)
8.1 North America Cardiotoxicity Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Diagnostic
8.1.2.1 Analyzers and Instruments
8.1.2.2 Reagents and Kits
8.1.2.3 Software and Services
8.1.2.4 Others
8.1.3 Treatment
8.1.3.1 Tyrosine Kinase Inhibitors
8.1.3.2 Antibiotics
8.1.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
8.1.3.4 Others
8.2 North America Cardiotoxicity Market (2017-2032) by End User
8.2.1 Market Overview
8.2.2 Pharmaceutical and Biotechnology Company
8.2.3 Academic and Research Institutes
8.2.4 Contact Research Organizations
8.2.5 Others
8.3 North America Cardiotoxicity Market (2017-2032) by Country
8.3.1 United States of America
8.3.2 Canada
9 Europe Cardiotoxicity Market (2017-2032)
9.1 Europe Cardiotoxicity Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Diagnostic
9.1.2.1 Analyzers and Instruments
9.1.2.2 Reagents and Kits
9.1.2.3 Software and Services
9.1.2.4 Others
9.1.3 Treatment
9.1.3.1 Tyrosine Kinase Inhibitors
9.1.3.2 Antibiotics
9.1.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
9.1.3.4 Others
9.2 Europe Cardiotoxicity Market (2017-2032) by End User
9.2.1 Market Overview
9.2.2 Pharmaceutical and Biotechnology Company
9.2.3 Academic and Research Institutes
9.2.4 Contact Research Organizations
9.2.5 Others
9.3 Europe Cardiotoxicity Market (2017-2032) by Country
9.3.1 United Kingdom
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Others
10 Asia Pacific Cardiotoxicity Market (2017-2032)
10.1 Asia Pacific Cardiotoxicity Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Diagnostic
10.1.2.1 Analyzers and Instruments
10.1.2.2 Reagents and Kits
10.1.2.3 Software and Services
10.1.2.4 Others
10.1.3 Treatment
10.1.3.1 Tyrosine Kinase Inhibitors
10.1.3.2 Antibiotics
10.1.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
10.1.3.4 Others
10.2 Asia Pacific Cardiotoxicity Market (2017-2032) by End User
10.2.1 Market Overview
10.2.2 Pharmaceutical and Biotechnology Company
10.2.3 Academic and Research Institutes
10.2.4 Contact Research Organizations
10.2.5 Others
10.3 Asia Pacific Cardiotoxicity Market (2017-2032) by Country
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 ASEAN
10.3.5 Australia
10.3.6 Others
11 Latin America Cardiotoxicity Market (2017-2032)
11.1 Latin America Cardiotoxicity Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Diagnostic
11.1.2.1 Analyzers and Instruments
11.1.2.2 Reagents and Kits
11.1.2.3 Software and Services
11.1.2.4 Others
11.1.3 Treatment
11.1.3.1 Tyrosine Kinase Inhibitors
11.1.3.2 Antibiotics
11.1.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
11.1.3.4 Others
11.2 Latin America Cardiotoxicity Market (2017-2032) by End User
11.2.1 Market Overview
11.2.2 Pharmaceutical and Biotechnology Company
11.2.3 Academic and Research Institutes
11.2.4 Contact Research Organizations
11.2.5 Others
11.3 Latin America Cardiotoxicity Market (2017-2032) by Country
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Mexico
11.3.4 Others
12 Middle East and Africa Cardiotoxicity Market (2017-2032)
12.1 Middle East and Africa Cardiotoxicity Market (2017-2032) by Type
12.1.1 Market Overview
12.1.2 Diagnostic
12.1.2.1 Analyzers and Instruments
12.1.2.2 Reagents and Kits
12.1.2.3 Software and Services
12.1.2.4 Others
12.1.3 Treatment
12.1.3.1 Tyrosine Kinase Inhibitors
12.1.3.2 Antibiotics
12.1.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
12.1.3.4 Others
12.2 Middle East and Africa Cardiotoxicity Market (2017-2032) by End User
12.2.1 Market Overview
12.2.2 Pharmaceutical and Biotechnology Company
12.2.3 Academic and Research Institutes
12.2.4 Contact Research Organizations
12.2.5 Others
12.3 Middle East and Africa Cardiotoxicity Market (2017-2032) by Country
12.3.1 Saudi Arabia
12.3.2 United Arab Emirates
12.3.3 Nigeria
12.3.4 South Africa
12.3.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trial Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Strategic Initiatives
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Market Share Analysis, By Region (Top 5 Companies)
18.1.1 Market Share Analysis: Global
18.1.2 Market Share Analysis: North America
18.1.3 Market Share Analysis: Europe
18.1.4 Market Share Analysis: Asia Pacific
18.1.5 Market Share Analysis: Others
18.2 Admescope Ltd
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Evotec BioSystems GmbH
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisition
18.3.5 Certifications
18.4 Stemina Biomarker Discovery, Inc .
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisition
18.4.5 Certifications
18.5 Eurofins Panlabs Discovery Services
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisition
18.5.5 Certifications
18.6 Molecular Devices LLC.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisition
18.6.5 Certifications
18.7 Axol Bioscience Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisition
18.7.5 Certifications
18.8 Curia Global Holdings Ltd
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisition
18.8.5 Certifications
18.9 Aragen Life Sciences Limited
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisition
18.9.5 Certifications
18.10 Anbio Biotechnology Limited
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisition
18.10.5 Certifications
18.11 WuXi AppTec Co., Ltd.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisition
18.11.5 Certifications
18.12 Creative Bioarray
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisition
18.12.5 Certifications
18.13 Emka Technologies Private Limited
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisition
18.13.5 Certifications
18.14 Enzo Life Sciences, Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisition
18.14.5 Certifications
18.15 Novartis AG
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisition
18.15.5 Certifications
18.16 Pfizer & Co., Inc.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Mergers and Acquisition
18.16.5 Certifications
18.17 Amgen Inc
18.17.1 Financial Analysis
18.17.2 Product Portfolio
18.17.3 Demographic Reach and Achievements
18.17.4 Mergers and Acquisition
18.17.5 Certifications
19 Cardiotoxicity Market – Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER